Search Results for: covid-19
Articles
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology March 4, 2021
Qualigen Therapeutics, Inc. recently announced it has entered into a Material Evaluation and Option Agreement with the University College London...SPECIAL FEATURE - Improving Bioavailability & Solubility: Each Molecule Is Unique March 1, 2021
Contributor Cindy H. Dubin speaks with several innovative companies to discuss novel approaches to improving bioavailability and solubility that have one commonality: they treat each molecule as an individual.
GLOBAL REPORT - 2020 Global Drug Delivery & Formulation Report: Part 1, a Global Review March 1, 2021
In part 1 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on a global review of 2020 product approvals.
CELL & GENE THERAPY - End-to-End Cell & Gene Therapy – From Development to Commercialization – Buy or Build? March 1, 2021
Aldo Romano and Emily Moran, MBA, discuss how the life science industry must bring technology solutions to the table while at the same time securing the capacity to develop and manufacture groundbreaking cures so patients and society can tap the benefits of cell and gene therapies.
EXECUTIVE INTERVIEW - Pharmaceutics International, Inc: Getting Back to its Roots March 1, 2021
Sridhar Krishnan, Pii’s Senior Vice President, Operations and Strategic Initiatives, discusses how manufacturing is not solely where Pii wanted to be, so the company made a concerted effort to get back to its CDMO roots.
IMMUNE ACTIVATORS - Enhancing Cell Adhesion to Safely Improve Effectiveness of Vaccines & Cancer Immunotherapies March 1, 2021
Siddhartha De, PhD, and Peter Vanderslice, PhD, present their research on the use of proprietary, orally available compounds that can activate the immune system to enhance the effectiveness of vaccines as well as immuno-oncology therapies for cancer, especially in patient populations that are most vulnerable to disease.
Mateon Therapeutics & Windlas Biotech Launch India's First Combined Lung Therapy & AI Telemedicine Solution February 24, 2021
Mateon Therapeutics, Inc. and Windlas Biotech Pvt. Ltd. recently announced the launch in India of PulmoHeal, a first-of-its-kind integrated, consumer-centric...Halberd Collaborates With GreenBioAZ for the Development of Its Patent Pending Radio Frequency Technology February 24, 2021
Halberd Corporation has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent-pending Radio Frequency (RF) extracorporeal treatment to eliminate...Intra-Cellular Therapies Applies for FDA Approval of Bipolar Depression Treatment February 24, 2021
Intra-Cellular Therapies, Inc. recently announced it has submitted supplemental New Drug Applications (sNDAs) to the US FDA for two indications...Halberd Collaborates With GreenBioAZ for the Development of Radio Frequency Technology to Eliminate Disease Pathogens February 17, 2021
Halberd Corporation has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate….
Enlivex Announces Issuance of New US Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis & GvHD Using Allocetra Immunotherapy February 17, 2021
Enlivex Therapeutics Ltd. recently announced the US Patent and Trademark Office has issued US Patent No. 10,927,343 covering Allocetra, the...OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines & Therapeutics February 11, 2021
OliX Pharmaceuticals, Inc. recently announced the establishment of mCureX Therapeutics, Inc., a subsidiary focused on the research and development of...Biogen Announces FDA Approval of PLEGRIDY (Peginterferon Beta-1a) Intramuscular Administration for Multiple Sclerosis February 4, 2021
Biogen Inc. recently announced the US FDA has approved a new intramuscular (IM) injection route of administration for PLEGRIDY (peginterferon beta-1a) for the treatment of….
Relief Therapeutics & Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration & License Agreement January 28, 2021
Relief Therapeutics Holding AG and Acer Therapeutics Inc. recently announced the companies have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license….
DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study January 28, 2021
DURECT Corporation recently announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the...Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial January 21, 2021
Caladrius Biosciences, Inc. recently announced it has treated the first patient in its Phase 2b FREEDOM trial of CLBS16 as...SPECIAL FEATURE - Outsourcing Analytical Testing: Innovative Drugs Spike Demand for Advanced Analysis January 14, 2021
Contributor Cindy H. Dubin asked some of the key analytical testing providers to describe their offerings in several key areas and what advanced analytical testing techniques they can offer to pharma clients.
EXECUTIVE INTERVIEW - BiologIC Technologies: The Future Microsoft for the Biorevolution January 13, 2021
Richard Vellacott, CEO of BiologIC Technologies, discusses his company’s unique technology and its applications in the future of medicine and wider fields of synthetic biology.
EXECUTIVE INTERVIEW - Fortress Biotech, Inc.: Looking for the Muffin Tops January 13, 2021
Lindsay A. Rosenwald, MD, Chairman, President, and CEO of Fortress Biotech, discusses how his medical and financial knowledge come together to find successful drug candidates, the company’s partnership model, and the inefficiencies he sees in the biotech industry.
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion January 7, 2021
Catalyst Pharmaceuticals, Inc. recently announced an expansion in its strategic priorities related to portfolio planning and research and development. Catalyst...
